Trial Profile

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial& NDASH; a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targeted anti-cancer drugs in patients with advanced cancers progressive on standard therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Everolimus (Primary) ; Niraparib (Primary)
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms MEGALiT

22 Aug 2024 Status changed from recruiting to active, no longer recruiting.
10 May 2024 Planned End Date changed from 1 Dec 2022 to 1 Oct 2024.
12 May 2023 This trial has been completed, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com